MACROGENICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
MACROGENICS, INC. (MGNX) reported Net Income (Loss) Available to Common Stockholders, Diluted of $1.17 for the 3-month period ending 2016-06-30, per its 10-Q filed 2016-08-03.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2016-08-03
- MACROGENICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2016-06-30 was $1.17.
- MACROGENICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2016-03-31 was -$0.88, a 157.52% decline year-over-year.
- MACROGENICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2015-09-30 was -$0.46.
- MACROGENICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2015-06-30 was -$0.71.
- MACROGENICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2014 was -$38.31M.
- MACROGENICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2013 was -$261.00K.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-06-30 | $1.17 10-Q · filed 2016-08-03 | $0.29 10-Q · filed 2016-08-03 | ||||||
| 2016-03-31 | -$0.88 10-Q · filed 2016-05-04 | |||||||
| 2015-09-30 | -$0.46 10-Q · filed 2015-11-04 | -$1.17 derived: sum of 2 quarters · filed 2016-08-03 | $0.27 10-Q · filed 2015-11-04 | -$38.31M derived: sum of 4 quarters · filed 2016-08-03 | ||||
| 2015-06-30 | -$0.71 10-Q · filed 2016-08-03 | $0.80 10-Q · filed 2016-08-03 | -$38.31M derived: sum of 3 quarters · filed 2016-08-03 | -$38.31M derived: sum of 4 quarters · filed 2016-08-03 | ||||
| 2015-03-31 | $1.53 10-Q · filed 2016-05-04 | -$38.31M derived: sum of 2 quarters · filed 2016-05-04 | -$38.31M derived: sum of 3 quarters · filed 2016-05-04 | -$38.31M derived: sum of 4 quarters · filed 2016-05-04 | ||||
| 2014-12-31 | -$38.31M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$38.31M derived: sum of 2 quarters · filed 2015-11-04 | -$38.31M derived: sum of 3 quarters · filed 2015-11-04 | -$38.31M 10-K · filed 2015-03-03 | ||||
| 2014-09-30 | -$0.14 10-Q · filed 2015-11-04 | -$3.93M 10-Q · filed 2014-11-12 | -$0.58 derived: sum of 2 quarters · filed 2015-11-04 | -$0.71 10-Q · filed 2015-11-04 | -$19.30M 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | -$0.44 10-Q · filed 2015-08-05 | -$12.26M 10-Q · filed 2014-08-05 | -$0.57 10-Q · filed 2015-08-05 | -$15.37M 10-Q · filed 2014-08-05 | ||||
| 2014-03-31 | -$0.12 10-Q · filed 2015-05-06 | -$3.11M 10-Q · filed 2014-05-06 | ||||||
| 2013-12-31 | -$261.00K 10-K · filed 2015-03-03 | -$260.83K 10-K · filed 2014-03-20 | ||||||
| 2013-09-30 | $200.00K 10-Q · filed 2014-11-12 | $200.14K 10-Q · filed 2013-11-12 | -$94.00K derived: sum of 2 quarters · filed 2014-11-12 | -$3.46M derived: sum of 3 quarters · filed 2014-11-12 | ||||
| 2013-06-30 | -$294.00K 10-Q · filed 2014-08-05 | -$3.66M 10-Q · filed 2014-08-05 | ||||||
| 2013-03-31 | -$3.37M 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |